

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

**Thursday, August 10, 2017
11am – 12pm**

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for April 19, 2017 meeting
- IV. Secretary's report
- V. Old Business
 - A. Smoking cessation therapy denials report
 - B. Proposed protocol for safe and efficient use of eteplirsen (Exondys 51[®])
- VI. New Business
 - A. Proposed protocol for safe and efficient use of deflazacort (Emflaza[®])
 - B. Proposed protocol for safe and efficient use of nusinersen (Spinraza[®])
 - C. Updated protocol for sofosbuvir (Sovaldi[®]) – include children and adolescents
 - D. Updated protocol for sofosbuvir/ledipasvir (Harvoni[®]) - include children and adolescents
- VII. Informational Highlights/Reports
 - 1. Molina/NJ HMO 1st Quarter 2017 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered drugs by amount paid/category
 - 4. Medication information:
 - (a) Desperate families driven to black market insulin
 - (b) “Superbug” fungus new menace in US hospitals, mostly NY, NJ
 - (c) Death from infections may be masking opioid claims
 - (d) Opioid epidemic may be underestimated, CDC report says
 - (e) FDA: Boxed warning for canagliflozin on amputation risk
 - (f) Why are EpiPens so expensive?